<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Teng C</submitter><funding>Hainan Provincial Natural Science Foundation of China</funding><funding>the Research Foundation of Hainan University</funding><funding>National Natural Science Foundation of China</funding><pagination>5466</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9785909</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(24)</volume><pubmed_abstract>Small synthetic TLR7/8-agonists can be used as vaccine adjuvants to enhance cell and humoral-mediated immune responses to specific antigens. Despite their potency, after local injection they can be dispersed to undesired body parts causing high reactogenicity, limiting their clinical applications. Here we describe a vaccination strategy that employs the covalent conjugate of a mannose and TLR7/8 agonist as a vaccine adjuvant to take advantage of mannose binding C-type lectins on dendritic cells to enhance the vaccine's immunogenicity. The mannose-TLR7/8 agonist conjugate can self-assemble into nanoparticles with the hydrophilic mannose on the outside and hydrophobic TLR7/8 agonist inside. Although its ability to stimulate HEK-Blue&lt;sup>TM&lt;/sup> hTLR7/8 cells dropped, it can efficiently stim</pubmed_abstract><journal>Polymers</journal><pubmed_title>Self-Assembled TLR7/8 Agonist-Mannose Conjugate as An Effective Vaccine Adjuvant for SARS-CoV-2 RBD Trimer.</pubmed_title><pmcid>PMC9785909</pmcid><funding_grant_id>82073697</funding_grant_id><funding_grant_id>821MS028</funding_grant_id><funding_grant_id>KYQD(ZR)20087</funding_grant_id><funding_grant_id>82103988</funding_grant_id><funding_grant_id>821CXTD1011</funding_grant_id><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Yang J</pubmed_authors><pubmed_authors>Zong C</pubmed_authors><pubmed_authors>Meng S</pubmed_authors><pubmed_authors>Teng C</pubmed_authors><pubmed_authors>Hu Y</pubmed_authors><pubmed_authors>Sun T</pubmed_authors><pubmed_authors>Mao H</pubmed_authors><pubmed_authors>Meng X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Self-Assembled TLR7/8 Agonist-Mannose Conjugate as An Effective Vaccine Adjuvant for SARS-CoV-2 RBD Trimer.</name><description>Small synthetic TLR7/8-agonists can be used as vaccine adjuvants to enhance cell and humoral-mediated immune responses to specific antigens. Despite their potency, after local injection they can be dispersed to undesired body parts causing high reactogenicity, limiting their clinical applications. Here we describe a vaccination strategy that employs the covalent conjugate of a mannose and TLR7/8 agonist as a vaccine adjuvant to take advantage of mannose binding C-type lectins on dendritic cells to enhance the vaccine's immunogenicity. The mannose-TLR7/8 agonist conjugate can self-assemble into nanoparticles with the hydrophilic mannose on the outside and hydrophobic TLR7/8 agonist inside. Although its ability to stimulate HEK-Blue&lt;sup>TM&lt;/sup> hTLR7/8 cells dropped, it can efficiently stim</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2025-04-18T15:59:27.903Z</modification><creation>2025-04-07T02:55:56.429Z</creation></dates><accession>S-EPMC9785909</accession><cross_references><pubmed>36559833</pubmed><doi>10.3390/polym14245466</doi></cross_references></HashMap>